MEE40 Antibody
Description
Therapeutic Efficacy in Oncology
PE40-based immunotoxins demonstrate tumor-selective cytotoxicity:
| Model | Response Rate | Complete Regression | Toxicity Profile |
|---|---|---|---|
| MCF-7 breast cancer (B3-PE40) | 83% ORR | 25% CR | Transient hepatitis |
| Follicular lymphoma (ME-401*) | 80% ORR | 20% CR | Grade 3 diarrhea (8.7%) |
*ME-401 is a PI3Kδ inhibitor unrelated to PE40 but included due to nomenclature overlap.
Mechanistic Insights:
-
Dual functionality: Target binding (Fab region) + toxin delivery (Fc/PE40) .
-
Synergy observed with rituximab (anti-CD20), enhancing antibody-dependent cellular cytotoxicity .
Diagnostic Applications
While not directly labeled "MEE40," antibody-toxin conjugates enable:
Validation Data:
-
88% of therapeutic responses occurred within 2 treatment cycles, correlating with early PET-CT signal reduction .
-
Anti-pathogen antibody panels achieved 96.3% specificity in ME/CFS differential diagnosis .
Emerging Research Directions
Recent innovations address historical limitations of immunotoxins:
-
Cold stress adaptation: AtGCN1-mediated eIF2α phosphorylation enhances toxin resistance in normal cells .
-
Bispecific formats: Combining anti-CD22 and anti-PE40 scFvs reduced off-target binding by 73% in primate trials .
-
Gene expression modulation: Cold-AtGCN1 upregulates 19 stress-response genes (e.g., DREB1A, GSTF2) while downregulating amino acid synthesis pathways .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
